WEST CHESTER, Pa., May 12 (Reuters) - Cephalon Inc and
Chiron Corp CHIR.O said in a statement Tuesday that the U.S.
Food and Drug Administration has indicated their new drug
application to market a treatment for Lou Gherig's disease is
"potentially approvable." Cephalon, which issued the statement, said any approval for its Myotrophin Injection for the treatment of amyotrphic lateral sclerosis, is subject to submission of additional
information from ongoing studies demonstrating its effectiveness.
"We plan to meet with the FDA to clarify the conditions for
approval and to determine whether these conditions can be
satisfied," said Dr Frank Baldino Jr, president and chief
executive officer of Cephalon, and Dr Lewis Williams, president
of Chiron Technologies, a division of Chiron Corp.
REUTERS
Rtr 00:36 05-13-98
Copyright 1998, Reuters News Service |
